N/A N=559 Observation Versus Occlusion Therapy for Intermittent Exotropia
Exotropia
Primary: Deterioration by 6 Months - Older Cohort — 10; 1; 7; 1 Participants — p=0.004
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=60 The Effect of N-Acetyl Cysteine on Cortical Erosion in Early Stage Schizophrenia
Schizophrenia · Psychotic Disorder NOS · Schizoaffective Disorder
Primary: Cortical Thickness — 2.53; 2.54; 2.51; 2.52 mm
Phase 2 N=126 Aprepitant for the Relief of Nausea in Patients With Chronic Nausea and Vomiting of Presumed Gastric Origin Trial
Gastroparesis
Primary: Number of Participants With Improvement in Nausea — 29; 25 participants — p=0.43
Phase 2 N=268 A Phase 2a, Proof-of-Concept Study of GIC-1001 in the Management of Visceral Pain During Sedation-Free, Full Colonoscopy
Pain · Cancer · Colonic Diseases
Primary: Measurements of Visceral Pain, Using a 100-mm Visual Analog Scale (VAS) — 22.27; 18.93; 23.31; 22.22 mm — p=0.506
Phase 2 N=24 BATTLE-FL: Front-Line Biomarker-Integrated Treatment Study in Non Small Cell Lung Cancer
Lung Cancer
Primary: Progression Free Survival — 5.2; 14.5; 20.6; 8 month
Phase 4 N=5 Mirabegron in Parkinson Disease and Impaired Cognition
Parkinson Disease · Overactive Bladder · Impaired Cognition
Primary: Change in Montreal Cognitive Assessment Total Score — 1.5; 2 units on a scale
Phase 2 N=35 Intranasal Hydromorphone for the Treatment of Acute Pain in Children: A Pilot Study.
Pain
Primary: Score on Faces Pain Scale - Revised — 4.7 units on a scale
Phase 3 N=126 Role of Magnesium Supplementation in the Treatment of Depression
Depression
Primary: Patient Health Questionnaire-9 — -4.28; -0.09 score on a scale
Phase 1 N=8 A Study of [14 C]-Pevonedistat in Participants With Advanced Solid Tumors
Advanced Solid Tumors, Neoplasms, Advanced Solid
Primary: Part A: Cmax: Maximum Observed Plasma and Whole Blood Concentration for Pevonedistat — 234.3; 6862.9 nanogram per milliliter (ng/mL)
Phase 1 N=33 Pharmacokinetics, Safety and Tolerability of Escalating Rifapentine Doses in Healthy Volunteers
Tuberculosis · Tuberculosis, Pulmonary
Primary: Number of Participants With Grade 2 or Higher Adverse Events Over the Course of the 26 Day Trial — 1; 0; 1; 1 Participants
N/A N=197 Bilateral Lateral Rectus Recession Versus Unilateral Recess-Resect for Intermittent Exotropia
Exotropia
Primary: Number of Participants With Suboptimal Surgical Outcome as Assessed by Motor Alignment and Stereoacuity at Near by 3 Years — 43; 33 Participants — p=0.24
Phase 4 N=41 Systemic Vascular Endothelial Growth Factor (VEGF) Protein Dynamics Following Intravitreal Injections of Ranibizumab Versus Aflibercept in Patients With Neovascular Age-related Macular Degeneration
Wet Age-Related Macular Degeneration
Primary: Standardized Area Under the Curve (AUC) for VEGF A Levels by SIMOA (Quanterix's Single Molecule Array) Method for the Comparative Phase — 18.78; 33.95 pg/mL — p=<0.0001
N/A N=18 Renal Perfusion, Filtration and Oxygenation During Cardiopulmonary Bypass (CPB)
Complication of Extracorporeal Circulation · Renal Impairment
Primary: Renal Blood Flow (RBF) — 554; 524; 564; 558 ml per minute per 1.73 m2 body surface — p=0.638
Phase 2 N=55 A Study to Investigate the Safety and Efficacy of Lacosamide Added to the Patients Current Therapy in Patients Aged 1 Month to Less Than 18 Years Old With Epilepsy Syndromes Associated With Generalized Seizures.
Epilepsy
Primary: Mean Changes in Count of Generalized Spike-wave Discharges on 24-hour Ambulatory Electroencephalogram (EEG) From Visit 2 to Visit 6 — -4.55; -166.22; -203.12 discharges
N/A N=9 Effect of Robot Rehabilitation Exercise Training on Motor Control After Stroke
Stroke
Primary: Change in Arm Motor Control From Baseline Measured as Average Squared Mahalanobis Distance — -16.31 unitless